- Home
- GCTK vs PBM Comparison
GCTK vs PBM Comparison
Compare GCTK & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- PBM
- Stock Information
- Founded
- GCTK 2001
- PBM 1994
- Country
- GCTK United States
- PBM Canada
- Employees
- GCTK N/A
- PBM N/A
- Industry
- GCTK Medical/Dental Instruments
- PBM
- Sector
- GCTK Health Care
- PBM
- Exchange
- GCTK Nasdaq
- PBM NYSE
- Market Cap
- GCTK 3.7M
- PBM 3.5M
- IPO Year
- GCTK N/A
- PBM N/A
- Fundamental
- Price
- GCTK $5.60
- PBM $5.28
- Analyst Decision
- GCTK
- PBM
- Analyst Count
- GCTK 0
- PBM 0
- Target Price
- GCTK N/A
- PBM N/A
- AVG Volume (30 Days)
- GCTK 1.6M
- PBM 47.0K
- Earning Date
- GCTK 08-12-2025
- PBM 07-22-2025
- Dividend Yield
- GCTK N/A
- PBM N/A
- EPS Growth
- GCTK N/A
- PBM N/A
- EPS
- GCTK N/A
- PBM 5.24
- Revenue
- GCTK N/A
- PBM N/A
- Revenue This Year
- GCTK N/A
- PBM N/A
- Revenue Next Year
- GCTK N/A
- PBM N/A
- P/E Ratio
- GCTK N/A
- PBM $0.98
- Revenue Growth
- GCTK N/A
- PBM N/A
- 52 Week Low
- GCTK $5.16
- PBM $2.93
- 52 Week High
- GCTK $3,756.00
- PBM $701.82
- Technical
- Relative Strength Index (RSI)
- GCTK 40.61
- PBM 51.95
- Support Level
- GCTK $5.61
- PBM $4.84
- Resistance Level
- GCTK $7.38
- PBM $5.69
- Average True Range (ATR)
- GCTK 1.25
- PBM 0.33
- MACD
- GCTK 0.04
- PBM -0.02
- Stochastic Oscillator
- GCTK 4.40
- PBM 51.59
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.